The use of FITC‐conjugated gated monoclonal antibodies for determination of S‐phase cells with fluorescence microscopy
- 1 November 1985
- Vol. 6 (6) , 597-601
- https://doi.org/10.1002/cyto.990060615
Abstract
A method is modified to determine the DNA synthesizing cells in primary human breast tumors and cells with idiopathic thrombocytopenic purpura (ITP) with FITC‐conjugated monoclonal antibody against bromodeoxyuridine (FITC‐M‐anti‐BrdUrd) and fluorescence microscopy. The DNA synthesizing cells were also determined from a portion of the same tissues by classical tritiated thymidine labeling (3HdThd) and autoradiography. The results from bromodeoxyuridine labeling index (BrdUrd‐LI) and tritiated thymidine labeling index (3HdThd‐LI) obtained from the same tissues were compared. The mean BrdUrd‐LI for breast tumor was 5.4 ± 1.0% and the mean 3HdThd‐LI was 5.5 ± 1.1%. Similarly, the labeling indexes obtained from mononuclear leukocytes of healthy donors had means of 0.5 ± 0.1% and 0.6 ± 0.1% for BrdUrd‐LI and 3HdThd‐LI, respectively. The change in the proliferation rate of mononuclear leukocyte population in the samples obtained from patients with ITP could be observed by both methods. The mean BrdUrd‐LI of mononuclear leukocytes for this hematological disorder was 5.4 ± 0.9% and the mean 3HdThd‐LI was 6.1 ± 0.8%. These results suggest that this relatively simple technique offers an alternative method for determining the DNA synthesizing cells in a given cell population.Keywords
This publication has 11 references indexed in Scilit:
- Rapid Enumeration of S-Phase Cells by Means of Monoclonal AntibodiesNew England Journal of Medicine, 1984
- RELATION OF ESTROGEN AND ITS RECEPTOR TO RAT-LIVER GROWTH AND REGENERATION1984
- Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapyBreast Cancer Research and Treatment, 1983
- Fluoresceinated estrone binding by cells from human breast cancers obtained by needle aspirationCancer, 1983
- Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine.Proceedings of the National Academy of Sciences, 1983
- Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: An interim reportBreast Cancer Research and Treatment, 1983
- INTERRELATION BETWEEN TUMOR-CELL PROLIFERATION AND 17-FLUORESCEINATED ESTRONE BINDING FOLLOWING PRIMARY TUMOR REMOVAL, RADIATION, CYCLOPHOSPHAMIDE, OR TAMOXIFEN1983
- INFLUENCE OF THE INTERVAL BETWEEN PRIMARY TUMOR REMOVAL AND CHEMOTHERAPY ON KINETICS AND GROWTH OF METASTASES1983
- Monoclonal Antibody to 5-Bromo- and 5-Iododeoxyuridine: A New Reagent for Detection of DNA ReplicationScience, 1982
- Further Observations on the Inhibition of Tumor Growth by Corynebacterium parvum With Cyclophosphamide. X. Effect of Treatment on Tumor Cell Kinetics in Mice2JNCI Journal of the National Cancer Institute, 1979